Objective: To determine the prevalence of hypercholesterolemia (HPC) and associated risk factors for cardiovascular disease, in young children and adolescents.
Design: Cross-sectional study, with stratification for age and gender.
Setting: Primary Care study.
Patients And Participants: 572 young children and adolescents, five through seventeen years of age in the year 2000, with no known previous personal history of cardiovascular disease, representing the Portuguese population for age and gender.
Intervention: Measurement of cholesterol on an occasional whole blood sample, along with anthropometric measures, blood pressure measurement, and study of family history for cardiovascular disease factors.
Measurements And Results: 291 males and 281 females. HPC prevalence of 17.6% (male = 15.1% and female = 20.3%, ns), girls presenting with higher mean values of total cholesterol (184.75 +/- 13.27 vs. 180.27 +/- 10.44, p = 0.06). Obesity prevalence of 35.4%, and arterial hypertension of 6.6%. HPC is more common among those with positive family history for cardiovascular disease risk factors (p = 0.01). Pulse pressure is lower in the hpc group (p = 0.01).
Conclusions: A hypercholesterolemia prevalence of 17.6% was found among children and adolescents, with strong association of family history for cardiovascular disease risk factors. In the light of these results, much further work will be needed to achieve reduction--or at least control--of this very important risk situation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cardiac acetylcholinesterase and butyrylcholinesterase have distinct localization and function.
Am J Physiol Heart Circ Physiol
January 2025
Comenius University Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology, Bratislava, Slovakia.
Cholinesterase (ChE) inhibitors are under consideration to be used in the treatment of cardiovascular pathologies. A prerequisite to advancing ChE inhibitors into the clinic is their thorough characterization in the heart. The aim here was to provide a detailed analysis of cardiac ChE to understand their molecular composition, localization, and physiological functions.
View Article and Find Full Text PDFGenomic Drivers of Coronary Artery Disease and Risk of Future Outcomes After Coronary Angiography.
JAMA Netw Open
January 2025
Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Importance: Disease characteristics of genetically mediated coronary artery disease (CAD) on coronary angiography and the association of genomic risk with outcomes after coronary angiography are not well understood.
Objective: To assess the angiographic characteristics and risk of post-coronary angiography outcomes of patients with genomic drivers of CAD: familial hypercholesterolemia (FH), high polygenic risk score (PRS), and clonal hematopoiesis of indeterminate potential (CHIP).
Design, Setting, And Participants: A retrospective cohort study of 3518 Mass General Brigham Biobank participants with genomic information who underwent coronary angiography was conducted between July 18, 2000, and August 1, 2023.
Safety of Human USH1C Transgene Expression Following Subretinal Injection in Wild-Type Pigs.
Invest Ophthalmol Vis Sci
January 2025
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Purpose: This study aimed to evaluate early-phase safety of subretinal application of AAVanc80.CAG.USH1Ca1 (OT_USH_101) in wild-type (WT) pigs, examining the effects of a vehicle control, low dose, and high dose.
View Article and Find Full Text PDFComparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors.
JAMA Intern Med
January 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Importance: Evidence on cardiovascular benefits and safety of sodium-glucose cotransporter 2 (SGLT-2) inhibitors is mainly from placebo-controlled trials. Therefore, the comparative effectiveness and safety of individual SGLT-2 inhibitors remain unknown.
Objective: To compare the use of canagliflozin or dapagliflozin with empagliflozin for a composite outcome (myocardial infarction [MI] or stroke), heart failure hospitalization, MI, stroke, all-cause death, and safety outcomes, including diabetic ketoacidosis (DKA), lower-limb amputation, bone fracture, severe urinary tract infection (UTI), and genital infection and whether effects differed by dosage or cardiovascular disease (CVD) history.
Exploring the Potential of Stem Cells in Modulating Gut Microbiota and Managing Hypertension.
Stem Cells Dev
January 2025
Department of Clinical Pharmacy and Pharmacy Practices, Faculty of Pharmacy, University Malaya, Kuala Lumpur, Malaysia.
Hypertension, commonly known as high blood pressure, is a significant health issue that increases the risk of cardiovascular diseases, stroke, and renal failure. This condition broadly encompasses both primary and secondary forms. Despite extensive research, the underlying mechanisms of systemic arterial hypertension-particularly primary hypertension, which has no identifiable cause and is affected by genetic and lifestyle agents-remain complex and not fully understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!